Key result
A single-drug approach with rivaroxaban provided successful anticoagulation without heparin and warfarin in a patient with cancer-associated thrombosis induced by chemotherapy.
Why the study?
Cancer-associated thrombosis is a leading cause of non-cancer death in patients with cancer, yet hemorrhagic risk also exists, requiring effective and safe anticoagulation strategies.
Does a single-drug approach with rivaroxaban provide effective and safe anticoagulation in a patient with cancer-associated thrombosis?
Case Report (n=1)
Does a single-drug approach with rivaroxaban provide effective and safe anticoagulation in a patient with cancer-associated thrombosis?
A single-drug approach with rivaroxaban may be an effective and safe strategy for managing cancer-associated thrombosis induced by chemotherapy.
May simplify anticoagulation in chemotherapy-induced cancer thrombosis; leaves open need for randomized confirmation.
We report a patient with pulmonary embolism and deep vein thrombosis induced by cancer chemotherapy who received successful anticoagulation using a single-drug approach with rivaroxaban. Cancer-associated thrombosis (CAT) is a leading cause of non-cancer death in patients with cancer, which is induced by cancer itself and/or chemotherapy agents including cisplatin and gemcitabine. By contrast, hemorrhagic state is another feature of advanced cancer. In these opposite conditions of cancer patients, CAT have to be controlled by appropriate anticoagulation. This case shows potential for single-drug approach with rivaroxaban and direct oral anticoagulants being effective and safety strategy against CAT. < Learning objective: Single-drug approach of direct oral anticoagulants (DOACs) against CAT induced by cisplatin and gemcitabine showed satisfactory anticoagulation without heparin and warfarin. CAT has been important issue in oncology field, and single-drug approach of DOACs could be an effective and safety strategy for anticoagulation against CAT.>
No takes yet. Share an insight, caveat, or question.
Shioyama et al. (2019) conducted a case report in Cancer-associated thrombosis (n=1). Rivaroxaban was evaluated on Successful anticoagulation. A single-drug approach with rivaroxaban provided successful anticoagulation without heparin and warfarin in a patient with cancer-associated thrombosis induced by chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: